Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products

The European Medicines Agency is considering whether apitegromab, brensocatib and diazoxide choline, from Scholar, Insmed and Soleno respectively, are drugs that are of potential major public health interest, particularly from the point of view of therapeutic innovation.

High speed on a car speedometer
Drug marketing applications are reviewed faster under the EMA's accelerated assessment pathway (Shutterstock)

More from EU CHMP

More from Geography